Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.48 |
| ▸ | PPARG | P37231 | 17/20 | 0.48 |
| ▸ | PPARD | Q03181 | 16/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | FABP1 | P07148 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379784 | 0.90 | PPARD (0.46) | PPARAPPARGPPARDFABP1NR1H4 | |
| SCHEMBL3378784 | 0.86 | PPARA (0.47) | PPARAPPARGPPARDFABP1NR1H4 | |
| SCHEMBL3377036 | 0.85 | PPARG (0.47) | PPARAPPARGPPARDFABP1NR1H4 | |
| SCHEMBL3376896 | 0.84 | PPARD (0.53) | PPARAPPARGPPARD | |
| SCHEMBL3410208 | 0.84 | PPARA (0.48) | PPARAPPARGPPARDFABP1NR1H4 | |
| SCHEMBL13069647 | 0.83 | PPARG (0.46) | PPARAPPARGPPARDFABP1NR1H4 | |
| SCHEMBL3375295 | 0.80 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL13069472 | 0.79 | PPARA (0.53) | PPARAPPARGPPARDFABP1NR1H4 | |
| SCHEMBL10662939 | 0.78 | PPARA (0.55) | PPARAPPARGPPARDCYP2C19 | |
| SCHEMBL3376815 | 0.77 | PPARA (0.53) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796665-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | LIPA, APOB, LCAT | PPARA 111/4885PPARG 152/4885PPARD 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.